欢迎来到《四川大学学报(医学版)》

Glut5在Ph+急性淋巴细胞白血病伊马替尼耐药中的机制研究

The Roles of Glut5 in Imatinib Resistance in the Ph+ Acute Lymphoblastic Leukemia Cell

  • 摘要: 目的采用费城染色体阳性急性淋巴细胞白血病(Ph+ALL)伊马替尼耐药细胞株SUP-B15/R研究伊马替尼耐药的可能机制。方法通过基因芯片分析法对比找出伊马替尼耐药株SUP-B15/R与敏感株SUP-B15/S之间表达差异的基因,筛选出可能与耐药相关的基因SLC2A5,分别采用实时荧光定量PCR(qPCR)和Western blot进一步验证SLC2A5及其编码蛋白葡萄糖转运体5(Glut5)在SUP-B15/R与SUP-B15/S之间表达的差异。采用MTT实验检测果糖对SUP-B15/S细胞伊马替尼敏感性的影响,以及qPCR检测相关信号通路的改变,探究Glut5表达增加在SUP-B15细胞伊马替尼耐药中的作用。结果基因芯片结果发现,与细胞代谢相关的SLC2A5基因在SUP-B15/R中高表达,qPCR和Western blot实验进一步验证了上述结果。而果糖处理后SUP-B15/S细胞对伊马替尼的敏感性下降,IC50由(44.50±2.38 )μmol/L增加到(64.71±1.69) μmol/L,同时Glut5、PI3K、AK mRNA表达增强。结论SUP-B15/R细胞高表达SLC2A5,Glut5高表达促进细胞对果糖的吸收,激活伊马替尼作用下受到抑制的PI3K/AKT信号通路,导致SUP-B15细胞对伊马替尼耐药。

     

    Abstract: Objective To explore the possible roles of glucose transport 5 (Glut5) in imatinib resistance in the Ph+ acute lymphoblastic leukemia cell (Ph+ ALL). Methods The gene chip technique was used to detect different gene expression between Ph+ ALL cell line SUP-B15/R (imatinib resistant cell line) and SUP-B15/S (imatinib sensitive cell line), the gene of solute carrier family 2 member 5 (SLC2A5) and its coded protein Glut5 were screened out and were reconfirmed by qPCR and Western blot assay. The imatinib half maximal inhibitory concentration (IC50) to SUP-B15/S cells with or without fructose treatment was further detected by MTT assay, simultaneously signal pathway gene was detected by qPCR assay. Results Metabolism related gene SLC2A5 was screened out with gene chip technique and the Western blot assay and qPCR confirmed the high expression of SLC2A5 gene and its coded protein Glut5 in SUP-B15/R cells. IC50 values of imatinib to SUP-B15/S cells after treatment with 25 μmol/L fructose were increased from (44.50±2.38) μmol/L to (64.71±1.69) μmol/L, in the meanwhile, PI3K and AKT mRNA level also increased in fructose treated SUP-B15/S cells compared to the control. Conclusions High expression of SLC2A5 and Glut5 protein in SUP-B15/R cells leads to increased fructose absorption, and further activates PI3K/AKT pathway which cause the SUP-B15 cell resistance to imatinib.

     

/

返回文章
返回